{
    "2019-02-08": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Phirbo, (PAHC), Q2 Earnings Lag Estimates, Operating Margin Up",
                "features": {
                    "keywords": [
                        "Q2",
                        "Earnings",
                        "Lag",
                        "Estimates",
                        "Operating",
                        "Margin",
                        "Up"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Omnicell, (OMCL), Q4 Earnings Beat Estimates, Revenues Miss",
                "features": {
                    "keywords": [
                        "Q4",
                        "Earnings",
                        "Beat",
                        "Estimates",
                        "Revenues",
                        "Miss"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Here's Why You Should Invest in Stryker, (SYK), Stock Right Now",
                "features": {
                    "keywords": [
                        "Invest",
                        "Stryker",
                        "Stock",
                        "Right",
                        "Now"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "See what the IHS Markit Score report has to say about Abbott Laboratories.",
                "features": {
                    "keywords": [
                        "IHS",
                        "Markit",
                        "Score",
                        "report",
                        "Abbott",
                        "Laboratories"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "[$$], Smith & Nephew in talks to buy NuVasive for over $3bn",
                "features": {
                    "keywords": [
                        "Smith",
                        "&",
                        "Nephew",
                        "talks",
                        "buy",
                        "NuVasive",
                        "$3bn"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}